TickerTalks
Browse all tickers →
TickerTalks›$QDEL
QDQDEL

QuidelOrtho Corporation

$QDEL·$838M·Medical - Instruments & Supplies·Healthcare
$14.30-5.2%YTD-39.1%1Y-44.9%
Mentions · last 7 days
2026-08-08: 2 posts2026-08-09: 4 posts2026-08-10: 14 posts2026-08-11: 8 posts2026-08-12: 4 posts2026-08-13: 3 posts2026-08-14: 3 posts39+11%
Price updated 22h ago·X counts updated 21h ago
QDQDEL
$QDELQuidelOrtho Corporation
$14.30-5.24%39 posts+11%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $QDEL, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Broken storySelling offAI verdict · as of 2026-08-15

Falling on heavy selling — points lower unless it turns around.

Diagnostics maker beat Q2 by 367% but cut 2026 guidance — down 39% YTD and now near 52-week lows with a -5% single-day drop.

QuidelOrtho makes diagnostic instruments and consumables — the post-Ortho-merger diagnostics-and-immunology franchise that competes with Roche Diagnostics and Abbott across labs, hospitals, and molecular testing. It's down 39% year-to-date and 45% over twelve months on the guide-cut narrative and continued execution concerns despite a Q2 beat.

Where it stands:

  • The Q2 print itself was a decisive beat — EPS of $0.13 beat the -$0.05 estimate by 367% (following Q1's -110% miss, so this is a two-way surprise pattern), and revenue topped estimates, but the earnings-quality question is whether the beat is durable or one-quarter of favorable comparison against a weak base.
  • The 2026 guidance cut is the real story — QuidelOrtho lowered its full-year 2026 guidance alongside the Q2 print, which is why the tape gapped down and the stock now sits at 17% of the 52-week range with the position 29% below the 200-day moving average — the market is pricing continued deterioration despite the surprise Q2 beat.
  • The fundamentals show a stressed business — Q1 revenue declined 11% year-over-year, Q3 2025 EPS was -$10.78 on impairment charges, and 155% debt-to-equity is elevated for a diagnostics business that's shrinking on the top line — the balance sheet doesn't support extended patience if the revenue trend doesn't turn.

Q3 earnings Nov 4 is the read — a print showing sequential revenue stabilization plus commentary that reverses or clarifies the guide cut restarts a real turnaround thesis; another guide reduction or a specific product-line weakness (Molecular, Labs) and the 17%-of-52w-range tape becomes the multi-year-low tape. The debt load is what starts to matter next.

What to watch: Q3 earnings Nov 4 — a print showing sequential revenue stabilization plus commentary reversing or clarifying the guide cut restarts a real turnaround thesis; another guide reduction or specific product-line weakness (Molecular, Labs) and the 17%-of-52w-range tape becomes the multi-year-low tape. The debt load is what starts to matter next.

On the calendar: 2026-11-04 — Q3 earnings

sentiment missing

Read the AI verdict + X sentiment for $QDEL

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Diagnostics company manufacturing immunoassay, point-of-care, and molecular testing products for clinical labs and healthcare settings.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Instruments & Supplies sits in its cycle right now — and what that implies for $QDEL.

Medical - Instruments & Supplies · Healthcare

No material change from last week — Medline's prime vendor model wins market share as hospitals simplify sourcing, while bioprocessing component suppliers (WST, RGEN, AVTR) recover from the..

What this means for $QDEL

Neutral — Diagnostics company manufacturing immunoassay, point-of-care, and molecular testing products for clinical labs and healthcare settings; limited read-through from medical - instruments & supplies macro dynamics to this specific revenue mix.

Industry benchmark

10-name peer basket
+25.0%YTD
+26.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-1.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-19.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-36.9%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-6.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.5Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-56.3%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
45.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.6Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$0.13$-0.05+366.2%
Q1 2026May 5, 2026$-0.04$0.37-110.8%
Q4 2025Feb 11, 2026$0.46$0.43+7.0%
Q3 2025Nov 5, 2025$0.80$0.51+56.9%
Next earningsWed, Nov 4·consensus EPS $0.18

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$619.8M-10.5%42.6%-4.4%$-1.35$-26.8M
Q4 FY25$723.6M+2.2%44.3%-9.2%$-1.95$86.6M
Q3 FY25$699.9M-3.7%47.9%-101%$-10.78$-94.7M
Q2 FY25$613.9M-3.6%44.8%-29.4%$-3.77$-40.3M

Forward consensus

5-year forecast · up to 3 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$2.7B$2.7B – $2.7B$1.85$1.83 – $1.883
FY27$2.8B$2.8B – $2.8B$2.46$2.43 – $2.493
FY28$2.9B$2.9B – $3.0B$2.94$2.91 – $2.992
FY29$3.0B$3.0B – $3.1B$3.16$3.12 – $3.201
FY30$2.8B$2.8B – $2.9B$0.90$0.89 – $0.911

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.17%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-9.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-29.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 67.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.695-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 33 other (21 awards · 11 exempts · 1 inkind) in window

See when $QDEL insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsJul 153
AI summary

Micah Young filed an initial Form 3 on July 15, 2026, disclosing no beneficially owned securities of QuidelOrtho Corporation (QDEL). This filing initiates Young's reporting obligations as a newly appointed officer or director under Section 16(a) of the Securities Exchange Act.

8-KOfficer or director changeJun 238-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

QuidelOrtho appointed Micah Young (age 48) as incoming CFO effective July 6, 2026, succeeding retiring CFO Joseph Busky who will cooperate through the transition period. Clean planned CFO succession.

8-KShareholder voteJun 168-K — Item 5.07: Shareholder vote
3New insider — initial holdingsMar 313
3New insider — initial holdingsMar 243
8-KOfficer or director changeMar 248-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
+ 25 other (14 13Gs · 3 earnings 8-Ks · 2 10-Qs · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

QDEL Q2 Earnings & Revenues Beat Estimates, 2026 Guidance Loweredzacks.com·5d agoQuidelOrtho (NASDAQ:QDEL) Shares Gap Down – Time to Sell?defenseworld.net·7d agoQuidelOrtho Corporation (QDEL) Q2 2026 Earnings Call Transcriptseekingalpha.com·8d agoQuidelOrtho Q2 Earnings Call Highlightsmarketbeat.com·9d agoQuidelOrtho (QDEL) Surpasses Q2 Earnings and Revenue Estimateszacks.com·9d ago

More in Medical - Instruments & Supplies

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$BDX$ISRG$MDLN$AVTR$LMAT$PLSE$AZTA$WST
Voices on X · last 7 days

No standout posts about $QDEL on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport